Antipsychotic medication for early episode schizophrenia

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2007, Pages

  Bola, John ^a   Soydan, H ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

CLINICAL PROTOCOL; DATA ANALYSIS; DRUG EFFECT; HUMAN; METHODOLOGY; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW;

EID: 44949137456     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006374     Document Type: Review

References (45)

1. Altman 1996 Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
2. APA 2004 American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia, Second edition. Supplement to the American Journal of Psychiatry 2004;161(2):1-56.
3. Bland 1997 Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
4. Bola 1998 Bola JR. Evaluation of treatment in early episode acute psychosis: A secondary analysis of the Soteria study [Dissertation]. Berkeley, CA: School of Social Welfare, University of California, 1998:147.
5. Bola 2006 Bola JR. At Issue: Medication-free research in early episode schizophrenia: Evidence of long-term harm?. Schizophrenia Bulletin 2006;32(2):288-96.
6. Borenstein 2004 Borenstein M, Rothstein H. Comprehensive Meta-Analysis. Comprehensive Meta-Analysis. Englewood Cliffs, N.J.: Biostat, 2004.
7. Carpenter 1994 Carpenter WT Jr, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681-90.
8. Cochrane 2006 The Cochrane Collaboration. Revman 4.2.9. Oxford, England: The Cochrane Collaboration, 2006.
9. Cole 1966 Cole JO, Goldberg SC, Davis JM. Drugs in the treatment of psychosis: Controlled studies. In: SolomonP editor(s). Psychiatric drugs: Proceedings of a research conference held in Boston. New York: Grune and Stratton, 1966:153-80.
10. Cornblatt 2001 Cornblatt BA, Lencz T, Kane JM. Treatment of the schizophrenia prodrome: Is it presently ethical?. Schizophrenia Research 2001;51:31-8.
11. CPA 1998 Canadian Psychiatric Association. Canadian clinical practice guidelines for the treatment of schizophrenia. Canadian Journal of Psychiatry 1998;43(Suppl. 2):19.
12. DeGrazia 2001 DeGrazia D. Ethical issues in early-intervention clinical trials involving minors at risk for schizophrenia. Schizophrenia Research 2001;51:77-86.
13. DeQuardo 1998 DeQuardo JR. Pharmacologic treatment of first-episode schizophrenia: Early intervention is key to outcome. Journal of Clinical Psychiatry 1998;59(Suppl. 19):9-17.
14. Divine 1992 Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-9.
15. Dixon 1995 Dixon LB, Lehman AF, Levine J. Conventional antipsychotic medications for schizophrenia. Schizophrenia Bulletin 1995;21(4):567-77.
16. Donner 2002 Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
17. Egger 1997 Egger M, Davey-Smith G, Schneider M, Minder CSO. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;13:629-34.
18. Falloon 1998 Falloon IRH, Cloverdale JH, Laidlaw TM, Merry S, Kydd RR, Morosini P. Early intervention for schizophrenic disorders: Implementing optimal treatment strategies in routine clinical services. British Journal of Psychiatry 1998;172(33S):33-8.
19. Frances 1996 Frances A, Docherty JP, Kahn DA. The expert consensus guidelines series:Treatment of schizophrenia. Journal of Clinical Psychiatry 1996;57(Suppl. 12B):5-58.
20. Gaebel 2002 Gaebel W, Janner M, Frommann N, Pietzckier A, Kopcke W, Linden M, Muller P, Muller-Spahn F, Tegeler J. First vs multiple episode schizophrenia: Two-year outcome of intermittent and maintenance medication strategies. Schizophrenia Research 2002;53:145-59.
21. Gaebel 2005 Gaebel W, Weinmann S, Sartorius N, Rutz W, McIntyre JS. Schizophrenia practice guidelines: International survey and comparison. British Journal of Psychiatry 2005;187:248-55.
22. Gulliford 1999 Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
23. Higgins 2002 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21:1539-58.
24. Higgins 2005 Higgins JPT, Green S. Cochrane Handbook for systematic reviews of interventions 4.2.5. Cochrane Handbook for systematic reviews of interventions 4.2.5. Chichester, UK: JohnWiley and Sons, Ltd, 2005.
25. Kane 1993 Kane JM, Marder SR. Pharmacologic treatment of schizophrenia. Schizophrenia Bulletin 1993;19(2):287-302.
26. Kirch 1992 Kirch DG, Keith SJ, Matthews SM. Research on first episode psychosis: Report on a National Institute of Mental Health workshop. Schizophrenia Bulletin 1992;18(2):179-84.
27. Lehman 1998 Lehman AF, Steinwachs DM. The schizophrenia patient outcomes research team (PORT) treatment recommendations. Schizophrenia Bulletin 1998;24(1):1-10.
28. Lewander 1996 Lewander T. Long-term studies of antipsychotic drugs in schizophrenia. European Psychiatry 1996;11:127-34.
29. Linszen 1998 Linszen D, Lenior M, DeHaan L, Dingemas P, Gersons B. Early intervention, untreated psychosis and the course of early schizophrenia. British Journal of Psychiatry 1998;172:84-9.
30. Marshall 2000 Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
31. McGlashan 2001 McGlashan TH. Psychosis treatment prior to psychosis onset: Ethical issues. Schizophrenia Research 2001;51:47-54.
32. McGorry 2001 McGorry PD, Yung A, Phillips L. Ethics and early intervention in psychosis: Keeping up the pace and staying in step. Schizophrenia Research 2001;51:17-29.
33. National 2002 National Institute for Clinical Excellence (NICE). Schizophrenia: Core interventions in the treatment and management of schizophrenia in primary and secondary care. London: National Institute for Clinical Excellence, 2002.
34. Norman 2001 Norman RMG, Malla AK. Duration of untreated psychosis: A critical examination of the concept and its importance. Psychological Medicine 2001;31(3):381-400.
35. Oxman 1992 Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Annals of Internal Medicine 1992;116:78-84.
36. Pietzcker 1993 Pietzcker A, Gaebel W, Kopcke W, Linden M, Muller P, Muller-Spahn F, Tegeler J. Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia: 2-year results of a German multicenter study. Journal of Psychiatric Research 1993;27(4):321-39.
37. Popp 1998 Popp SM, Trezza GR. Side effects of and reactions to psychotropic medications. Emergencies in mental health practice 1998;n/a:279-311.
38. Rummel 2003 Rummel C, Harmann J, Kissling W, Leucht S. New generation antipsychotics for first-episode schizophrenia (Cochrane Review). Cochrane Database of Systematic Reviews 2003, Issue 3.
39. Schooler 1967 Schooler NR, Goldberg SC, Boothe H, Cole JO. One year after discharge: Community adjustment of schizophrenic patients. The American Journal of Psychiatry 1967;123(8):986-995.
40. Thornley 2006 Thornley B, Rathbone J, Adams CE, Awad G. Chlorpromazine versus placebo for schizophrenia (Cochrane Review). Cochrane Database of Systematic Reviews 2006, Issue 4.Art. No.: CD000284. DOI: 10.1002/14651858.CD000284.pub2.
41. Ukoumunne 1999 Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
42. Warner 2001 Warner R. The prevention of schizophrenia: What interventions are safe and effective?. Schizophrenia Bulletin 2001;27(4):551-62.
43. Wyatt 1991 Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophrenia Bulletin 1991;17(2):325-51.
44. Yung 1998 Yung AR, Phillips LJ, McGorrey PD, McFarlane CA, Francey S, Harrigan S, Patton GC, Jackson HJ. Prediction of psychosis: A step towards indicated prevention of schizophrenia. The British Journal of Psychiatry 1998;172:14-20.
45. Yusuf 1991 Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. Journal of the American Medical Association 1991;266:93-8. [MEDLINE: Amer Medical Assoc].